Goldman Sachs Upgrades Vivendi (VIVHY) to Buy; CEO Departs; Possibility For More Aggressive Actions
Tweet Send to a FriendGet Alerts VIVHY Hot Sheet
Price: $19.87 +0.61%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade VIVHY Now!
Goldman Sachs upgraded Vivendi (OTCBB: VIVHY) from Neutral to Buy with a price target of EUR20.00 (from EUR17.20).
Analyst, Richard Jones, said, "In our view, the departure of the CEO could see Vivendi undertake a more aggressive approach to its corporate structure, potentially leading to significant disposals. As such, we have increased our SOTP valuation from €19.2 to €25 to reflect potential acquisition valuations (rather than trading multiples) but incorporate a 20% conglomerate discount."
For an analyst ratings summary and ratings history on Vivendi click here. For more ratings news on Vivendi click here.
Shares of Vivendi closed at $18.41 yesterday, with a 52 week range of $15.84-$27.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Richard Jones, said, "In our view, the departure of the CEO could see Vivendi undertake a more aggressive approach to its corporate structure, potentially leading to significant disposals. As such, we have increased our SOTP valuation from €19.2 to €25 to reflect potential acquisition valuations (rather than trading multiples) but incorporate a 20% conglomerate discount."
For an analyst ratings summary and ratings history on Vivendi click here. For more ratings news on Vivendi click here.
Shares of Vivendi closed at $18.41 yesterday, with a 52 week range of $15.84-$27.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- Macquarie Upgrades IntercontinentalExchange (ICE) to Outperform
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

